Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
That's what his former Commerce secretary says in this interview. Plus: IRS audits, TV news ratings, nasty insults, Minecraft, Prada, and the Panama Canal.
Jeremy Jansen, Head of Global Supply Chain and Trade Sales at Wells Fargo, helps us understand how trade will be affected by tariffs implemented by Trump.
Kory Kantenga, Head of Economics for the Americas at LinkedIn, talks the current state of the labor market and how it has evolved since the pandemic. Watch!
Caraway CEO, Jordan Nathan, joins Cheddar to discuss how one bad accident turned into a successful business venture and how it will help you in the kitchen.
